MiMedx Group (MDXG) Projected to Post Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect MiMedx Group to post earnings of $0.09 per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

MiMedx Group Price Performance

MDXG opened at $5.16 on Wednesday. The company has a market capitalization of $764.20 million, a price-to-earnings ratio of 19.11 and a beta of 1.59. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $6.01 and a 200-day moving average price of $6.68. MiMedx Group has a twelve month low of $4.89 and a twelve month high of $8.50.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MDXG shares. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho reduced their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Lake Street Capital reduced their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Finally, Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, MiMedx Group currently has an average rating of “Moderate Buy” and an average price target of $9.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Magnetar Financial LLC purchased a new stake in MiMedx Group in the 3rd quarter worth approximately $167,000. Tower Research Capital LLC TRC raised its position in shares of MiMedx Group by 116.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 18,162 shares of the company’s stock worth $111,000 after purchasing an additional 9,761 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of MiMedx Group in the first quarter valued at approximately $128,000. AQR Capital Management LLC boosted its stake in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in MiMedx Group during the fourth quarter worth about $98,000. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.